Variability of skin scores and clinical measurements in scleroderma
- PMID: 7562757
Variability of skin scores and clinical measurements in scleroderma
Abstract
Objective: To determine the variability of several clinical outcome measurements commonly used in scleroderma clinical trials.
Methods: Ten researchers, members of a multicenter placebo controlled trial of methotrexate in early diffuse scleroderma, studied the intraobserver and interobserver variability of variables used to assess efficacy in scleroderma trials.
Results: For most measures, the variability within an observer was less than that found between observers, and therefore the intraobserver reliability was better than the interobserver reliability. The reliability of the modified Rodnan skin score exceeded the Rodnan skin score. Measures with inherent interpretation such as global assessments and skin scores had more variability than easily performed measurements such as grip strength and oral opening.
Conclusion: Some of our variability was higher than variability previously reported; this could be due to the large number of examiners and patients in our study.
Similar articles
-
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.Arthritis Rheum. 2001 Jun;44(6):1351-8. doi: 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I. Arthritis Rheum. 2001. PMID: 11407694 Clinical Trial.
-
Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.J Rheumatol. 1995 Jul;22(7):1281-5. J Rheumatol. 1995. PMID: 7562759
-
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.Rheumatology (Oxford). 2004 Apr;43(4):472-8. doi: 10.1093/rheumatology/keh070. Epub 2003 Dec 16. Rheumatology (Oxford). 2004. PMID: 14679295 Clinical Trial.
-
Outcome measurement in scleroderma clinical trials.Semin Arthritis Rheum. 1993 Aug;23(1):22-33. doi: 10.1016/s0049-0172(05)80024-1. Semin Arthritis Rheum. 1993. PMID: 8235663 Review.
-
Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis.Curr Opin Rheumatol. 1997 Nov;9(6):571-5. doi: 10.1097/00002281-199711000-00014. Curr Opin Rheumatol. 1997. PMID: 9375287 Review.
Cited by
-
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231. J Scleroderma Relat Disord. 2017. PMID: 28516167 Free PMC article.
-
High-throughput quantitative histology in systemic sclerosis skin disease using computer vision.Arthritis Res Ther. 2020 Mar 14;22(1):48. doi: 10.1186/s13075-020-2127-0. Arthritis Res Ther. 2020. PMID: 32171325 Free PMC article.
-
Skin imaging in systemic sclerosis.Eur J Rheumatol. 2014 Sep;1(3):111-116. doi: 10.5152/eurjrheumatol.2014.036. Epub 2014 Sep 1. Eur J Rheumatol. 2014. PMID: 27708890 Free PMC article. Review.
-
Quantitating skin fibrosis: innovative strategies and their clinical implications.Curr Rheumatol Rep. 2014 Mar;16(3):404. doi: 10.1007/s11926-013-0404-5. Curr Rheumatol Rep. 2014. PMID: 24442715 Review.
-
How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography.Arthritis Res Ther. 2020 Mar 18;22(1):50. doi: 10.1186/s13075-020-02150-x. Arthritis Res Ther. 2020. PMID: 32188488 Free PMC article.